7 completed, 3 terminated, 1 not yet recruiting, 1 recruiting. 12 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Terminated 3, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Osteomyelitis: new trials by email Literature Review of Osteomyelitis trials Research Report on Osteomyelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS Zoledronic Acid / Zoledronate 4 MG/100 ML Intravenous Solution, NaCL 0.9% Intravenous Solution - Osteomyelitis Chronic | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-09-15 | 2026-06-25 |
| A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers. STIMULAN VG, Standard of Care - Pressure Ulcer, Stage IV, Osteomyelitis | Phase 2 | Recruiting | Biocomposites Ltd | 60 | 2025-06-15 | 2026-11-10 |
| Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis Bacteriophage Therapy, Placebo - Osteomyelitis, Diabetic Foot Osteomyelitis | Phase 2 | Terminated | Adaptive Phage Therapeutics, Inc. | 41 | 2021-11-24 | 2025-08-19 |
| Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Dalbavancin, Standard of Care - Osteomyelitis | Phase 2 | Terminated | Allergan | 1 | 2017-05-15 | 2018-09-26 |
| Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER) Tedizolid - Bone and Joint Infection | Phase 2 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 44 | 2017-02-06 | 2023-12-13 |
| Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites MBN-101, Placebo - Bacterial Infection | Phase 2 | Completed | Microbion Corporation | 29 | 2016-05-24 | 2021-09-30 |
| Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis Dalbavancin, Comparator - Osteomyelitis | Phase 2 | Completed | Durata Therapeutics Inc., an affiliate of Allergan plc | 80 | 2016-03-15 | 2019-01-04 |
| Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections sodium fusidate - Refractory Bone or Joint Infections | Phase 2 / Phase 3 | Completed | Arrevus Inc. | 30 | 2015-12-01 | 2020-01-30 |
| Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children Ceftaroline Fosamil - Hematogenously Acquired Staphylococcus Aureus Osteomyelitis, Bone Infection | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 11 | 2015-06-03 | 2021-11-02 |
| Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis Intravenous Antibacterial Agent, Oral Antibacterial Agent - Osteomyelitis | Phase 2 | Terminated | Loyola University | 30 | 2014-03-19 | 2018-07-19 |
| Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI Feraheme, Magnetic Resonance Imaging (MRI) scan - Bone Cancer, Chondrosarcoma | Phase 2 | Completed | Heike E Daldrup-Link | 32 | 2011-08-01 | 2023-12-27 |
| Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci daptomycin, vancomycin, teicoplanin - Osteomyelitis | Phase 2 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 75 | 2007-06-26 | 2018-01-31 |
Diabetes Mellitus (2) · Bacterial Infections (1) · Bone Neoplasms (1) · Chondrosarcoma (1) · Fractures, Bone (1) · Infections (1) · Inflammation (1) · Osteonecrosis (1) · Osteosarcoma (1) · Pressure Ulcer (1) · Rhabdomyosarcoma (1) · Sarcoma, Ewing (1)
Bone Diseases (12) · Bone Diseases, Infectious (12) · Musculoskeletal Diseases (12) · Infections (11) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bacterial Infections and Mycoses (1) · Myosarcoma (1) · Necrosis (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Daptomycin (2) · Standard of Care (2) · Vancomycin (2) · dalbavancin (2) · Anti-Bacterial Agents (1) · Aztreonam (1) · Cefepime (1) · Ceftaroline (1) · Ciprofloxacin (1) · Clindamycin (1) · Ferrosoferric Oxide (1) · Floxacillin (1) · Fusidic Acid (1) · Linezolid (1) · Magnetic Resonance Spectroscopy (1)
Adaptive Phage Therapeutics, Inc. (1) · Allergan (1) · Arrevus Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · Biocomposites Ltd (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Durata Therapeutics Inc., an affiliate of Allergan plc (1) · Heike E Daldrup-Link (1) · Loyola University (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Microbion Corporation (1)
United States (10) · France (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
Alistair Wheeler, MD (1) · Brett Baker, MSc, DC (1) · Heike E Daldrup-Link, MD (1) · Loren G Miller, MD MPH (1) · Michael Pinzur, M.D. (1) · Neyssa Marina, MD (1) · Nitsan Halevy, MD (1) · Robert Dobbins, MD, PhD (1) · Sheldon L. Kaplan, MD (1) · Urania Rappo, MD (1) · Urania Rappo, MD, MS, PharmD (1)
2023 (1)